{"title":"估计遗传性嗜铬细胞-副神经节瘤综合征基因携带者在一个大型多民族基因组数据库中的全球患病率。","authors":"Nipith Charoenngam, Taweesak Wannachalee","doi":"10.1093/ejendo/lvaf191","DOIUrl":null,"url":null,"abstract":"<p><strong>Objectives: </strong>To estimate the global prevalence of genetic carriers of pheochromocytoma-paraganglioma syndromes (PPGLs) in a large multiethnic genomic database.</p><p><strong>Methods: </strong>We analyzed sequencing data from 807 162 unrelated individuals in the gnomAD v4.1 database, representing a global population of diverse ethnic ancestries. Eleven PPGLs-associated genes were examined: FH, NF1, RET, SDHA, SDHAF2, SDHB, SDHC, SDHD, TMEM127, VHL, and MAX. Pathogenic or likely pathogenic variants (P/LP) were identified from ClinVar, while additional predicted deleterious variants were included based on loss-of-function annotations and splice prediction in silico tools. Prevalence estimates of genetic carriers were calculated by combining allele frequencies of qualifying variants.</p><p><strong>Results: </strong>The prevalence of SDHA carriers was the highest when aggregating allele frequencies of both ClinVar P/LP and predicted deleterious variants (158.83 per 100 000), followed by NF1 (93.66 per 100 000) and FH (72.23 per 100 000), while VHL and MAX had the lowest prevalence. Substantial variation was observed across ancestries, with certain variants enriched in specific populations (eg, SDHC p.Tyr126Cys in non-Finnish Europeans; FH c.556-4A > G in East Asians). Carriers of SDHB, SDHC, and TMEM127 ClinVar P/LP or predicted deleterious variants were absent in the Middle Eastern group; SDHAF2 and SDHC were absent in the Ashkenazi Jewish group; and SDHAF2 and TMEM127 were absent in the Finnish group. Predicted deleterious variants significantly increased carrier estimates for SDHAF2, SDHD, and TMEM127.</p><p><strong>Conclusion: </strong>Our study highlights the variability in PPGL-associated mutation carrier prevalence across genes and ancestries. The findings underscore potential disparities in genetic risk that may not have been fully captured by clinical cohorts.</p>","PeriodicalId":11884,"journal":{"name":"European Journal of Endocrinology","volume":" ","pages":"412-420"},"PeriodicalIF":5.2000,"publicationDate":"2025-09-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Estimated global prevalence of genetic carriers of hereditary pheochromocytoma-paraganglioma syndrome in a large multiethnic genomic database.\",\"authors\":\"Nipith Charoenngam, Taweesak Wannachalee\",\"doi\":\"10.1093/ejendo/lvaf191\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Objectives: </strong>To estimate the global prevalence of genetic carriers of pheochromocytoma-paraganglioma syndromes (PPGLs) in a large multiethnic genomic database.</p><p><strong>Methods: </strong>We analyzed sequencing data from 807 162 unrelated individuals in the gnomAD v4.1 database, representing a global population of diverse ethnic ancestries. Eleven PPGLs-associated genes were examined: FH, NF1, RET, SDHA, SDHAF2, SDHB, SDHC, SDHD, TMEM127, VHL, and MAX. Pathogenic or likely pathogenic variants (P/LP) were identified from ClinVar, while additional predicted deleterious variants were included based on loss-of-function annotations and splice prediction in silico tools. Prevalence estimates of genetic carriers were calculated by combining allele frequencies of qualifying variants.</p><p><strong>Results: </strong>The prevalence of SDHA carriers was the highest when aggregating allele frequencies of both ClinVar P/LP and predicted deleterious variants (158.83 per 100 000), followed by NF1 (93.66 per 100 000) and FH (72.23 per 100 000), while VHL and MAX had the lowest prevalence. Substantial variation was observed across ancestries, with certain variants enriched in specific populations (eg, SDHC p.Tyr126Cys in non-Finnish Europeans; FH c.556-4A > G in East Asians). Carriers of SDHB, SDHC, and TMEM127 ClinVar P/LP or predicted deleterious variants were absent in the Middle Eastern group; SDHAF2 and SDHC were absent in the Ashkenazi Jewish group; and SDHAF2 and TMEM127 were absent in the Finnish group. Predicted deleterious variants significantly increased carrier estimates for SDHAF2, SDHD, and TMEM127.</p><p><strong>Conclusion: </strong>Our study highlights the variability in PPGL-associated mutation carrier prevalence across genes and ancestries. The findings underscore potential disparities in genetic risk that may not have been fully captured by clinical cohorts.</p>\",\"PeriodicalId\":11884,\"journal\":{\"name\":\"European Journal of Endocrinology\",\"volume\":\" \",\"pages\":\"412-420\"},\"PeriodicalIF\":5.2000,\"publicationDate\":\"2025-09-30\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"European Journal of Endocrinology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1093/ejendo/lvaf191\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"ENDOCRINOLOGY & METABOLISM\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"European Journal of Endocrinology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1093/ejendo/lvaf191","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}
Estimated global prevalence of genetic carriers of hereditary pheochromocytoma-paraganglioma syndrome in a large multiethnic genomic database.
Objectives: To estimate the global prevalence of genetic carriers of pheochromocytoma-paraganglioma syndromes (PPGLs) in a large multiethnic genomic database.
Methods: We analyzed sequencing data from 807 162 unrelated individuals in the gnomAD v4.1 database, representing a global population of diverse ethnic ancestries. Eleven PPGLs-associated genes were examined: FH, NF1, RET, SDHA, SDHAF2, SDHB, SDHC, SDHD, TMEM127, VHL, and MAX. Pathogenic or likely pathogenic variants (P/LP) were identified from ClinVar, while additional predicted deleterious variants were included based on loss-of-function annotations and splice prediction in silico tools. Prevalence estimates of genetic carriers were calculated by combining allele frequencies of qualifying variants.
Results: The prevalence of SDHA carriers was the highest when aggregating allele frequencies of both ClinVar P/LP and predicted deleterious variants (158.83 per 100 000), followed by NF1 (93.66 per 100 000) and FH (72.23 per 100 000), while VHL and MAX had the lowest prevalence. Substantial variation was observed across ancestries, with certain variants enriched in specific populations (eg, SDHC p.Tyr126Cys in non-Finnish Europeans; FH c.556-4A > G in East Asians). Carriers of SDHB, SDHC, and TMEM127 ClinVar P/LP or predicted deleterious variants were absent in the Middle Eastern group; SDHAF2 and SDHC were absent in the Ashkenazi Jewish group; and SDHAF2 and TMEM127 were absent in the Finnish group. Predicted deleterious variants significantly increased carrier estimates for SDHAF2, SDHD, and TMEM127.
Conclusion: Our study highlights the variability in PPGL-associated mutation carrier prevalence across genes and ancestries. The findings underscore potential disparities in genetic risk that may not have been fully captured by clinical cohorts.
期刊介绍:
European Journal of Endocrinology is the official journal of the European Society of Endocrinology. Its predecessor journal is Acta Endocrinologica.
The journal publishes high-quality original clinical and translational research papers and reviews in paediatric and adult endocrinology, as well as clinical practice guidelines, position statements and debates. Case reports will only be considered if they represent exceptional insights or advances in clinical endocrinology.
Topics covered include, but are not limited to, Adrenal and Steroid, Bone and Mineral Metabolism, Hormones and Cancer, Pituitary and Hypothalamus, Thyroid and Reproduction. In the field of Diabetes, Obesity and Metabolism we welcome manuscripts addressing endocrine mechanisms of disease and its complications, management of obesity/diabetes in the context of other endocrine conditions, or aspects of complex disease management. Reports may encompass natural history studies, mechanistic studies, or clinical trials.
Equal consideration is given to all manuscripts in English from any country.